Specific Insulin Signaling, Metabolic Syndrome, and Cardiovascular Disease

Christian Rask-Madsen and C. Ronald Kahn

Arterioscler Thromb Vasc Biol. 2012;32:2052-2059
doi: 10.1161/ATVBAHA.111.241919

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/32/9/2052
Tissue–Specific Insulin Signaling, Metabolic Syndrome, and Cardiovascular Disease

Christian Rask-Madsen, C. Ronald Kahn

Abstract—Impaired insulin signaling is central to development of the metabolic syndrome and can promote cardiovascular disease indirectly through development of abnormal glucose and lipid metabolism, hypertension, and a proinflammatory state. However, insulin’s action directly on vascular endothelium, atherosclerotic plaque macrophages, and in the heart, kidney, and retina has now been described, and impaired insulin signaling in these locations can alter progression of cardiovascular disease in the metabolic syndrome and affect development of microvascular complications of diabetes mellitus. Recent advances in our understanding of the complex pathophysiology of insulin’s effects on vascular tissues offer new opportunities for preventing these cardiovascular disorders. (Arterioscler Thromb Vasc Biol. 2012;32:2052-2059.)

Key Words: adhesion molecules ■ atherosclerosis ■ diabetes mellitus ■ endothelial function ■ insulin resistance

The rising prevalence of obesity worldwide is predisposing individuals to many diseases and disorders and has led to the prediction that children in America, for the first time, could have a shorter life expectancy than their parents.1 A large part of this risk is due to the fact that obesity is a central factor in development of insulin resistance, type 2 diabetes mellitus, and metabolic syndrome, all of which create an increased risk of cardiovascular disease.2 The metabolic syndrome itself includes central obesity, impaired glucose tolerance or diabetes mellitus, hypertension, and dyslipidemia with high plasma concentrations of triglyceride and low concentrations of high–density lipoprotein cholesterol, all of which can contribute to cardiovascular risk.3 Intense interest in the metabolic syndrome over the past 2 decades has improved awareness of the complex integrative physiology which determines the development and consequences of this condition. The effects of insulin action at the whole body level are summarized in Figure 1. In this review, we discuss the roles of insulin signaling and insulin resistance in a wide range of cells and tissues in the metabolic syndrome with a special focus on how they promote the associated cardiovascular complications.

This article accompanies the ATVB in Focus: Metabolic Syndrome and Insulin Resistance: Mechanisms and Consequences series that was published in the August 2012 issue.

The pathogenesis of metabolic syndrome remains debated. However, initiation of the typical case of metabolic syndrome is attributable to a degree of genetic predisposition created by multiple genes coupled with a sedentary lifestyle and a diet containing excess calories. A positive energy balance leads to increased storage of fat in adipose tissue but with development of obesity, the ability of adipocytes to store triglycerides is impaired or exceeded. Consequently, fat is stored in other cell types, including in liver and skeletal muscle.3 Ectopic lipid and their metabolites or increased concentrations of circulating free fatty acids cause insulin resistance in muscle and other tissues.3 Concurrently, fat tissue is infiltrated with macrophages and other immune cells because of adipocyte expression of monocyte chemoattractant protein-1 and other cytokines, or in response to adipose tissue hypoxia or adipocyte death.4 Circulating cytokines released by adipose tissue macrophages also contribute to insulin resistance in muscle, liver, and other tissues. In the brain, impaired insulin signaling and compromised nutrient sensing contributes to obesity by failing to suppress appetite. Brain insulin resistance also leads to glucose intolerance by impairing the ability of insulin to suppress hepatic glucose output through innervation of the liver. Other factors almost certainly contribute, including hyperinsulinemia which can itself promote insulin resistance.

At a molecular level insulin resistance can be caused by impaired insulin signaling because of increased serine phosphorylation of insulin receptor substrate-1 (IRS-1). This change causes inhibition of IRS-1 tyrosine phosphorylation, decreased binding of the downstream enzyme phosphatidylinositol 3-kinase, and decreased phosphorylation and activation of the kinase Akt. IRS-1 can be phosphorylated on serine residues by various isoforms of protein kinase C, which are activated by the lipid intermediate diacylglycerol,5 or by the stress kinase c-Jun N-terminal kinase when activated by proinflammatory cytokines4 or endoplasmic reticulum stress.6
Many other mechanisms have been proposed and their quantitative contribution to insulin resistance is still unresolved.

Insight into tissue-specific insulin signaling has been aided by mouse models of insulin receptor knockout restricted to certain cell types. They reveal the overall effects of insulin by loss of insulin action. However, they often do not accurately represent insulin signaling in the metabolic syndrome or other insulin-resistant states where some, but not all, postreceptor insulin signaling pathways are impaired. Such selective, or mixed, insulin resistance can occur in blood vessels where insulin-stimulated activation of Erk is preserved or enhanced or in the liver where insulin-stimulated activation of the transcription factor sterol regulatory element binding protein-1c (SREBP-1c) remains fully sensitive. Examples of insulin action and insulin signaling are discussed further below and illustrated in Figures 1 and 2, together with indications of whether selected mechanisms are insulin resistant or insulin sensitive in the metabolic syndrome.

**Insulin Signaling in Development of the Metabolic Syndrome**

Altered insulin signaling pathways contribute to many aspects of the metabolic syndrome. The most important changes in insulin signaling are summarized in Figure 2 and are discussed below.

**Insulin Signaling in Adipocytes and Macrophages Promotes Fat Tissue Expansion and Inflammation**

Adipose tissue expansion is caused by adipocyte hypertrophy rather than increased numbers of adipocytes, and large adipocytes are less sensitive to the antilipolytic action of insulin and express higher levels of the proinflammatory chemokine monocyte macrophage chemotactic protein-1. Mice with adipocyte-specific knockout of the insulin receptor have a decrease in the ability of insulin to suppress lipolysis, as well as impaired insulin–stimulated glucose uptake and triglyceride synthesis in adipocytes. This leads to a reduction in fat mass and protection against obesity induced by a
high-fat diet or hypothalamic injury. However, it is possible that impaired suppression of lipolysis in combination with a preserved ability of insulin to activate fatty acid synthesis through SREBP-1c may contribute to adipose tissue expansion during development of obesity.

A major component of obesity–related insulin resistance is the establishment of a chronic inflammatory state with invasion of white adipose tissue by mononuclear cells. These cells release proinflammatory cytokines that promote insulin resistance in skeletal muscle, liver, and other
tissues. Deletion of the insulin receptor in myeloid cells (monocytes, macrophages, and neutrophils) causes reduced accumulation of macrophages in white adipose tissue during high-fat feeding because of an impairment of matrix metalloproteinase-9 expression and activity in these cells. As a consequence, these animals have reduced circulating levels of tumor necrosis factor-α, reduced activation of stress kinases in muscle, and are protected from the development of insulin resistance upon high-fat feeding. Thus, insulin action in myeloid cells plays an unexpected, but important, role in the regulation of macrophage invasion of white adipose tissue and the development of obesity–associated insulin resistance.

**Impaired Insulin Signaling in Muscle Causes Insulin Resistance**

Skeletal muscle is the main tissue accounting for insulin–stimulated glucose disposal. In healthy people subjected to a euglycemic, hyperinsulinemic clamp, 80% of the glucose is taken up by skeletal muscle and used for glycogen synthesis and glycogenolysis. In insulin resistance, insulin signaling through IRS-1, phosphatidylinositol 3-kinase, and Akt is decreased, which ultimately results in a decrease in translocation of the glucose transporter GLUT4 to the plasma membrane and impaired insulin–stimulated glucose transport into the cell. Mice with muscle–specific insulin receptor knockout have profound insulin resistance in muscle, but glucose tolerance stays normal because insulin–independent glucose uptake in muscle remains intact along with increased glucose uptake in fat tissue. As a result, fat mass is increased in these animals and insulin–stimulated glucose uptake in fat is increased 3-fold.

**Hepatocyte Insulin Resistance Leads to Increased Glucose Output and Dyslipidemia**

Insulin action on hepatocytes suppresses gluconeogenesis and increases glycogen synthesis, resulting in decreased glucose output from the liver. Insulin resistance in the liver is the major cause of fasting hyperglycemia in the metabolic syndrome. In mice with insulin receptor deletion in hepatocytes, insulin suppression of hepatic glucose output is completely lost. At a molecular level this is represented by increased expression of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose 6-phosphatase and decreased expression of enzymes that regulate glycogen synthesis and glycogenolysis, including glucokinase and pyruvate kinase.

Dyslipidemia of the metabolic syndrome and type 2 diabetes mellitus is characterized by elevated plasma concentrations of fatty acids and triglyceride, relatively low plasma concentrations of low-density lipoprotein (LDL), and small, dense LDL. Regulation of the circulating lipids through insulin action on liver is affected by insulin resistance and hyperinsulinemia in several ways. First, insulin increases synthesis of fatty acids and triglyceride by activating SREBP-1c, which in turn increases transcription of lipogenic enzymes, including acetyl-coenzyme A carboxylase and fatty acid synthase. Unlike signaling through Akt and Forkhead box, class O (FoxO), this pathway appears to be unimpaired, or at least less impaired, in the metabolic syndrome. As a result, the hyperinsulinemia associated with metabolic syndrome causes increased circulating levels of free fatty acids and triglyceride. Hepatic insulin resistance also contributes to hyperlipidemia through downregulation of the LDL receptor. This occurs, at least in part, through an impaired ability of insulin to decrease transcription of apolipoprotein convertase subtilisin/kexin type 9, which promotes posttranslational downregulation of the LDL receptor. Therefore, liver insulin resistance causes decreased clearance of LDL and very low-density lipoprotein. Finally, absence of insulin receptors in hepatocytes increases secretion of apolipoprotein B, the main apolipoprotein in LDL and very low-density lipoprotein.

**Insulin Resistance in the Hypothalamus Contributes to Fasting Hyperglycemia and Impaired Appetite Regulation**

Insulin suppression of hepatic glucose output is also controlled by insulin action in the hypothalamus of the brain, which leads to a suppression of hepatic glucose output mediated by the vagal nerve. This effect can be blocked by injecting a K<sub>ATP</sub> channel blocker in the mediobasal hypothalamus, by gene knockout of a subunit of K<sub>ATP</sub> channels, or by resection of the hepatic branch of the vagal nerve. Central insulin action also promotes adipose tissue expansion through sympathetic innervation of adipose tissue. In addition, insulin suppresses appetite by activating neurons in the arcuate nucleus in the hypothalamus. At least part of this anorexic effect is mediated by melanocortin, and it is blunted in obesity.

**Insulin Resistance in β-cells Plays a Role in Progression of Glucose Intolerance to Type 2 Diabetes Mellitus**

Whether mild-to-moderate insulin resistance progresses to diabetes mellitus depends on the ability of pancreatic cells to maintain insulin levels high enough to overcome the insulin resistance and limit hyperglycemia. Insulin secretion and β-cell mass is upregulated in response to periodic hyperglycemia through glucose sensing by β-cells, resulting in increased insulin secretion and increased β-cell mass. Conversely, β-cells with insulin receptor knockout have decreased DNA and protein synthesis and slower growth in response to increased glucose concentrations. Mice with insulin receptor knockout in β-cells also lose first–phase insulin secretion and develop glucose intolerance. These mice have exacerbated glucose intolerance after developing diet-induced obesity with almost complete failure of compensatory β-cell hyperplasia.

**Endothelial Cell Insulin Resistance Can Limit Insulin Delivery to Target Tissues**

Insulin action and insulin resistance in endothelial cells can affect peripheral insulin action in several ways. First, insulin can cause an increase in blood flow or it can increase the fraction of capillaries perfused at a given time. Second, transendothelial transport of insulin can be mediated by endothelial cell insulin receptors and postreceptor signaling. Studies in humans first demonstrated that insulin-stimulated vasodilation could be a significant contributor to insulin–stimulated glucose uptake.
by a mechanism that could be blocked by an inhibitor of nitric oxide (NO) synthase and that was impaired in people with obesity or type 2 diabetes mellitus. Subsequent studies have suggested that an insulin-stimulated, transient increase in the number of perfused capillaries in a given tissue, a phenomenon known as capillary recruitment, may be more important for glucose tolerance than an insulin effect on total blood flow. In rats subjected to a euglycemic hyperinsulinemic clamp where plasma insulin concentrations were increased by 2-fold without changing blood glucose, there was a 2-fold increase in hind–limb blood volume, indicating capillary recruitment. This change was seen within 5 minutes after start of the insulin infusion before changes in blood flow occurred. Capillary recruitment can be blocked by inhibitors of NO synthase and is blunted in obese rats. Insulin–stimulated capillary recruitment may affect muscle glucose uptake by redistributing muscle perfusion from a nonnutritive to a nutritive route. Capillary recruitment could also contribute to the increased delivery of insulin to muscle and increase the endothelial surface available for transendothelial insulin transport.

Studies in dogs using labeled insulin and microdialysis of muscle interstitial fluid indicate that there is a significant delay of insulin delivery to the interstitium created by the passage through the vascular wall. Although some experiments suggest that this transfer of insulin from the intravascular to extravascular space occurs by passive diffusion, several lines of evidence support the notion that transendothelial transport of insulin is dependent on insulin receptors. This concept was pioneered using tissue culture studies which showed that transport of labeled insulin across monolayers of cultured endothelial cells was saturable because it could be blocked by excess unlabeled insulin and because the carrier could be blocked by insulin receptor antibodies. Ten minutes after a bolus of labeled insulin is injected, its localization in muscle is primarily in endothelial cells. Further, cell culture studies have shown that transendothelial insulin transport requires endothelial insulin signaling and may be mediated by a vesicular mechanism involving caveolin-1. In mice with knockout of IRS-2 targeted to endothelial cells, endothelial cell insulin signaling, capillary recruitment, insulin delivery to interstitium, and glucose tolerance are impaired. This correlates with decreased insulin–stimulated muscle glucose uptake in vivo but not ex vivo where muscle perfusion does not operate. Given these changes, it is surprising that glucose tolerance is not impaired in mice with endothelial cell insulin receptor knockout. Hypothetically, this discrepancy could be explained by insulin-stimulated occlusion of nonnutritive blood flow through induction of endothelin-1, independent of signaling through IRS proteins. This mechanism would contribute to glucose disposal in endothelial cell IRS-1 knockout mice but be absent in endothelial cell insulin receptor knockout mice.

Hyperinsulinemia May Cause Sympathetic Overactivity and Hypertension

Obesity is associated with overactivity of the sympathetic nervous system. This may contribute to glucose intolerance by stimulating gluconeogenesis and lipolysis through sympathetic innervation of liver and fat, respectively. Insulin action has a role in control of sympathetic activity, which increases in response to raised insulin levels after a mixed meal or during an euglycemic hyperinsulinemic clamp and decreases with fasting. Insulin can increase sympathetic nerve activity by acting on neurons in the arcuate nucleus of the hypothalamus. In obese individuals, sympathetic nerve activity is increased under basal conditions but does not increase further during an euglycemic hyperinsulinemic clamp as seen in insulin sensitive control subjects. Sympathetic overactivity in obesity can cause hypertension through vasoconstrictor effects mediated by sympathetic innervation of resistance vessels or the kidney. The latter can result in glomerular hyperfiltration, increased renal sodium reabsorption, and increased renin release. Increased sympathetic outflow can also contribute to left ventricular diastolic dysfunction, left ventricular hypertrophy, heart failure, and cardiac arrhythmia.

Insulin Signaling in Tissues Affected by Cardiovascular Disease and Microvascular Complications

Changes in insulin signaling is central to the development of the metabolic syndrome as discussed above. These disturbances can play a role in promoting cardiovascular disease in the metabolic syndrome and in developing vascular complications of diabetes mellitus by creating an environment of hyperglycemia, dyslipidemia, inflammation, and hypertension. However, abnormal insulin signaling in arteries and in vascular and other cells in the heart, kidney, and retina also contributes to disease in these organs.

Endothelial Cell Insulin Resistance Increases Vascular Wall Inflammation and Atherosclerosis

Insulin action directly on vascular endothelial cells affects endothelial function beyond regulating blood flow or capillary recruitment. Conditional knockout of the insulin receptor in endothelial cells causes a 2- to 3-fold increase in the atherosclerotic lesion size in apolipoprotein E–null mice. This large effect occurs without changes in glucose tolerance, insulin sensitivity, cholesterol levels, or blood pressure. Therefore, the increased atherogenesis in this model can be attributed to insulin action directly on endothelial cells rather than effects mediated through systemic parameters. The accelerated atherosclerosis in mice with endothelial cell insulin receptor knockout is preceded by a dramatic increase in leukocyte rolling and adhesion to endothelium and an increase in expression of vascular cell adhesion molecule-1. Although NO-mediated vasorelaxation is impaired in these mice, insulin-stimulated downregulation of vascular cell adhesion molecule-1 in endothelial cells is not blocked by inhibitors of NO synthase, suggesting that insulin signaling independent of NO is responsible for this effect.

Similar endothelial cell abnormalities are likely present in the metabolic syndrome. Thus, impaired endothelium-dependent vasodilation is present in people with obesity and type 2 diabetes mellitus. Furthermore, a blunted ability of insulin to activate Akt and endothelial NO synthase is observed in aorta of rats with obesity–associated insulin resistance and in mice with obesity induced by a high-fat diet or by leptin deficiency. Endothelial cell insulin resistance develops...
through similar mechanisms as in other tissues, including activation of Toll–like receptor 4 by free fatty acids,38 signaling activated by tumor necrosis factor-α or other proinflammatory cytokines,39 or downregulation of IRS proteins secondary to hyperinsulinemia.28

Insulin regulates certain genes by activation of Akt which phosphorylates FoxO, causing this transcription factor to be excluded from the nucleus. In LDL receptor knockout mice with deletion of all 3 major FoxO isoforms in endothelial cells, atherosclerosis is reduced by a remarkable 77%.40 In these animals, there is an increase in NO production and a decrease in generation of reactive oxygen species, activation of nuclear factor–κB, and expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and proinflammatory cytokines.40 These data suggest that endothelial cell genes that are regulated by FoxO could be good potential drug targets for prevention of atherosclerosis in people with the metabolic syndrome.

Insulin Resistance in Macrophages Promotes Necrotic Core Formation in Atherosclerosis

Loss of insulin action in macrophages may affect atherosclerosis progression by increasing the expression of CD36 or scavenger receptor A, which leads to increased uptake of modified lipoprotein,41 or by inhibiting proinflammatory activation.42 However, the overall effects on atherosclerotic lesion growth appear to be modest, based on studies of mice with conditional deletion of the insulin receptor in macrophages43 or mice with bone marrow transplantation using cells from mice with systemic defects in insulin signaling.41,43 Insulin resistance in macrophages, however, promotes formation of a necrotic core in atherosclerotic plaques by enhancing macrophage apoptosis.41 This is an important event in advanced atherosclerosis because exposure of the necrotic core to circulating blood in the event of plaque rupture can precipitate thrombosis, leading to unstable angina pectoris, transitory cerebral ischemia, stroke, or myocardial infarction.43 Proapoptotic pathways can be activated in insulin-resistant macrophages because they are more susceptible to endoplasmic reticulum stress and activation of the unfolded protein response.41

Cardiac Insulin Resistance Causes Substrate Inflexibility and Mitochondrial Uncoupling

Myocardial metabolism is changed in obesity. Isolated working hearts from ob/ob mice have higher rates of fatty acid oxidation and lower rates of glucose oxidation than hearts from normal lean mice.45 Hearts from obese animals also express higher levels of the β isoform of myosin heavy chain, which is dominant in fetal life and upregulated during remodeling in heart failure. Furthermore, the myocardium in obesity is unable to adapt to changes in substrate availability and is metabolically inefficient. In hearts from lean, wild-type mice, insulin increases glycolysis and glucose oxidation and reduces oxidation of free fatty acids. These effects are blunted in ob/ob mice, particularly during high concentrations of fatty acids.45

Mice with knockout of the insulin receptor have confirmed this role of insulin in cardiomyocyte function. Mice with conditional knockout of the insulin receptor driven by the muscle creatine kinase promoter were found to have up to a 28% reduction in heart size.46 This change can be explained by a similar reduction in cardiomyocyte volume. Adult cardiomyocytes from these knockout mice express higher levels of GLUT4 and of the fetal isoform of myosin heavy chain, and they have lower expression of GLUT1 and genes encoding for enzymes that catalyze mitochondrial β-oxidation. They also have mitochondrial uncoupling and oxidative stress related to reduced oxidative phosphorylation of fatty acid oxidation and reduced flux through the citric acid cycle.47 Surprisingly, insulin increased glucose oxidation and glycogenolysis in mice with cardiomyocyte insulin receptor knockout, indicating that insulin signaling in noncardiomyocytes can regulate cardiomyocyte metabolism by paracrine signaling.46 Mice with cardiomyocyte insulin receptor knockout under the control of the α-myosin heavy chain promoter showed similar findings although downregulation of the genes in the electron transport chain was more predominant than genes involved in mitochondrial β-oxidation.48 Cardiac systolic function in mice with cardiomyocyte knockout of the insulin receptor is only mildly impaired with reductions in ejection fraction of 12% or less.46,48 However, it is likely that the changes in metabolic substrate inflexibility and increased mitochondrial production of oxidants caused by cardiomyocyte insulin resistance can contribute to development of heart failure in the metabolic syndrome.

Insulin receptor signaling in cardiac muscle in insulin-resistant states is partially compensated for by insulin–like growth factor-1 receptor signaling. Mice with conditional knockout of both the insulin and insulin–like growth factor-1 receptor controlled by the muscle creatine kinase promoter die within the first 3 weeks of life because of cardiomyopathy and heart failure.49 These mice also exhibit a coordinated downregulation of genes encoding components of the electron transport chain and mitochondrial fatty acid β-oxidation pathways and altered expression of contractile proteins. Thus, some combination of insulin and insulin–like growth factor-1 receptor signaling is required for normal cardiac metabolism and function.

Retinal and Glomerular Insulin Action May Influence Microvascular Complications of Diabetes Mellitus

The course of microvascular complications of diabetes mellitus, particularly retinopathy and nephropathy, may be affected by changes in insulin action directly on the affected tissue. In the retina, insulin receptors are expressed primarily in photoreceptor cells and blood vessels.49 Insulin can act as a survival factor for retinal neurons and knockout of the insulin receptor in rod photoreceptors decreases survival of these cells.50 Insulin may also promote proliferative retinopathy, either by upregulating vascular endothelial growth factor51 or through direct effects on endothelial cells. Thus, knockout of the insulin receptor in endothelial cells reduced angiogenesis during retinal ischemia in mice by almost 60%. A similar, but lesser, effect was observed after knockout of the insulin–like growth factor-1 receptor in endothelial cells.50 This potentially important protective effect of endothelial insulin resistance in retinopathy requires further study.

In the kidney, podocytes are a critical component in the renal glomerular filtration barrier, and recent data have shown that insulin action on podocytes can be an important
Conclusion
Research on insulin receptor signaling using tissue–specific gene manipulation in mice as well as other methods has provided important insights into insulin action and revealed insulin effects in tissues that a decade or 2 ago were considered nonresponsive to insulin. New knowledge about tissue–specific insulin signaling and selective insulin resistance has helped us appreciate the complexity of abnormal insulin signaling in the metabolic syndrome and related disorders. These insights have practical consequences. First, insulin sensitizers would theoretically have better profiles of action if they improved insulin resistance in tissues regulating glucose and lipid metabolism, as well as in the endothelium and other vascular tissues where impaired insulin signaling is proatherosclerotic independent of metabolic effects. Second, insulin analogues should be carefully evaluated for deleterious effects on insulin signaling pathways which are not affected by insulin resistance, such as those pathways which promote dyslipidemia or increase vascular expression of endothelin-1. Third, genes regulated by insulin signaling in vascular tissue may be candidates for drug development. One study, for example, identified 21 endothelial cell genes which were directly regulated by FoxO, without many known function in this cell type. Some of these genes could be important determinants of proatherosclerotic effects of endothelial cell FoxO. These concepts provide exciting new possibilities for treating the metabolic syndrome and preventing cardiovascular disease.

Sources of Funding
Dr Rask-Madsen is supported by National Institutes of Health (NIH) grant EY018677 and Dr Kahn by NIH grants DK31036, DK33201, DK55545, DK82659, and R24DK085610, as well as the Mary K. Iacocca Professorship.

Disclosures
None.

References


